ClinicalTrials.gg
RecruitingNCT07145463Flex-TAVRUpdated Aug 28, 2025

Prospective, Multicenter, Randomized Controlled Clinical Study Evaluating the VitaFlow Liberty® Flex Transcatheter Aortic Valve Delivery System for the Treatment of Severe Aortic Stenosis Lesions

An interventional study of Transcatheter Aortic Valve Replacement in Aortic Valve Stenosis, sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Shanghai Zhongshan Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.

Planned enrollment
11th of 47
232 · median 120
Started
2025
with 10 others
No phase
37 of 69
20 open now
Primary completion
2026-08
later than 26 of 50 live
Registered
55th of 69
by date

Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 11th largest by planned enrollment of the 47 interventional ones that give a count, is one of 11 that started in 2025, is one of 37 with no phase, reaches primary completion later than 26 of the 50 other live ones, and was the 55th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Aortic Valve Stenosis with a site in China, or all of them as a file.
02

Study summary

This is a prospective, multicenter, randomized controlled clinical study designed to evaluate the real-world performance of the VitaFlow Liberty® Flex Transcatheter Aortic Valve Retrievable and Steerable Delivery System (Investigational Device) for treating severe aortic stenosis (AS) in challenging anatomies. The study will compare it against the VitaFlow Liberty® Retrievable Delivery System (Control Device), which lacks steerability.

Key Study Elements:

Objective: The primary objective is to assess the device's performance using the incidence of a composite endpoint before hospital discharge. This endpoint includes permanent pacemaker implantation (PPI), valve-in-valve (ViV) implantation, or moderate-to-severe paravalvular leakage (PVL).

Design: A prospective, multicenter RCT with 1:1 randomization (Experimental: VitaFlow Liberty® Flex vs. Control: VitaFlow Liberty®). Approximately 15 sites in China will participate. Subjects undergo follow-up at discharge, 30 days, and 1 year post-procedure. An independent data center handles management and analysis.

Population: Patients with severe AS (echo confirmed: peak velocity ≥4.0 m/s, mean gradient ≥40 mmHg, or AVA ≤1.0 cm²/AVAi ≤0.6 cm²/m²) AND preoperative CTA showing a challenging aortic-left ventricular angle >60°. NYHA class ≥II is required.

Devices:

Investigational: VitaFlow Liberty® Flex (Retrievable \& Steerable Delivery System - Models DSRS21/24/27/30/A series; Loading Tools LT-S series).

Control: VitaFlow Liberty® (Retrievable Delivery System - Models DSR21/24/27/30; Loading Tools LT series).

Endpoints:

Primary: Composite of PPI, ViV, or moderate-to-severe PVL before discharge.

Secondary: Include individual components of the primary endpoint (ViV, PVL) immediately post-procedure, procedural success (VARC-3), technical assistance rates, valve retrievals, implantation depth, arch/valve crossing performance, valve hemodynamics (gradient, area, leak, LVEF), NYHA class, Major Adverse Cardiac and Cerebrovascular Events (MACCE - all-cause death, MI, stroke, reoperation), major vascular complications (at discharge/30 days).

Key Inclusion: Severe AS, challenging anatomy (aortic-LV angle >60°), NYHA ≥II, informed consent.

Key Exclusions: Device/contrast allergies, anticoagulant intolerance, active infection, severe vascular disease prohibiting access, ascending aorta ≥55mm, unsuitable aortic root anatomy, intracardiac mass/thrombus, recent MI (\<30 days), severe concomitant mitral/tricuspid regurgitation, cardiogenic shock, severe LV dysfunction (LVEF\<20%), hematologic abnormalities, pregnancy/breastfeeding, participation in other device trials.

Visits: Screening (≤30d pre-op), Procedure (intra-op to 24h post-op), Discharge (≤7d post-op), 30d Follow-up (±7d), 12m Telephone FU (±1m).

Sample Size: Planned enrollment of 232 subjects (116 per group), calculated for superiority testing. Based on an expected composite endpoint rate of 21% for the Flex system vs. a historical rate of 38% for non-steerable systems (Superiority margin Δ1=0%, one-sided α=2.5%, Power=80%, accounting for 5% dropout).

Purpose: This study aims to demonstrate the superiority of the retrievable and steerable VitaFlow Liberty® Flex delivery system in reducing the composite rate of key adverse events (PPI, ViV, significant PVL) at discharge compared to the non-steerable system, specifically in patients with severe AS and anatomically challenging aortic-left ventricular angles.

Read the detailed description

A Prospective, Multicenter, Randomized Controlled Clinical Trial Evaluating the VitaFlow Liberty® Flex Transcatheter Aortic Valve Retrievable and Steerable Delivery System for Severe Aortic Stenosis in Challenging Anatomies

  1. Study Rationale and Objective Severe aortic stenosis (AS) carries significant morbidity and mortality when untreated. Transcatheter aortic valve replacement (TAVR) has emerged as a standard therapy, yet complex aortic anatomies - particularly steep aortic-left ventricular (LV) angles - present technical challenges during valve delivery, potentially leading to suboptimal deployment, paravalvular leak (PVL), conduction disturbances requiring permanent pacemaker implantation (PPI), or valve-in-valve (ViV) placement. The VitaFlow Liberty® Flex Delivery System addresses this with its retrievable and steerable catheter technology designed for enhanced navigability. This prospective, multicenter, randomized controlled trial (RCT) aims to evaluate the real-world superiority of the investigational VitaFlow Liberty® Flex System versus the non-steerable VitaFlow Liberty® System in patients with severe AS and challenging anatomies (aortic-LV angle >60°). The primary objective is to compare the incidence of a composite safety endpoint (PPI, ViV implantation, or moderate-to-severe PVL) before hospital discharge.
  2. Study Design

Type: Prospective, multicenter, open-label, 1:1 randomized controlled superiority trial

Randomization: Centralized electronic system

Blinding: Unblinded (procedural nature precludes blinding)

Study Arms:

Experimental: VitaFlow Liberty® Flex TAVR System (Retrievable \& Steerable)

Control: VitaFlow Liberty® TAVR System (Retrievable, Non-Steerable)

Follow-up Schedule:

Pre-discharge (≤7 days post-op)

30 days (±7 days)

12 months (±1 month, telephone)

Oversight: Independent Clinical Events Committee (CEC), Data Monitoring Committee (DMC), and Core Laboratories for imaging/ECG analysis

Centers: \~15 experienced TAVR centers across China

3. Investigational and Control Devices

Device Component:VitaFlow Liberty® FLEX (Investigational) VitaFlow Liberty® (Control) Delivery System Type:Retrievable \& Steerable(Investigational) Retrievable (Non-Steerable)(Control)

4. Study Population

Diagnosis: Severe symptomatic AS confirmed by echocardiography:

Peak aortic velocity ≥4.0 m/s OR Mean gradient ≥40 mmHg OR Aortic valve area (AVA) ≤1.0 cm² (or AVAi ≤0.6 cm²/m²) Anatomical Inclusion: Pre-op CT angiography (CTA) with 3D reconstruction demonstrating aortic-LV angle >60° (validating challenging anatomy).

Symptoms: NYHA Functional Class ≥II.

Key Exclusion Criteria:

Allergy to device materials (nitinol), contrast, or antiplatelets/anticoagulants Active infection/endocarditis Severe vascular disease prohibiting access Ascending aorta diameter ≥55mm Unsuitable aortic root anatomy (e.g., heavy calcification affecting expansion) Intracardiac thrombus/mass Recent MI (\<30 days) Severe mitral/tricuspid regurgitation LVEF \<20% Hematologic disorders (leukopenia, thrombocytopenia, coagulopathy) Pregnancy or concurrent device trials

5. Endpoints

Primary Endpoint:

Composite of PPI, ViV implantation, or moderate-to-severe PVL before discharge.

Secondary Endpoints:

Procedural:

ViV rate (immediate post-op) Moderate-to-severe PVL (immediate post-op) Technical assistance crossing rate Valve retrieval attempts Valve implantation depth Arch/valve crossing performance Procedural success (VARC-3 criteria*)

Clinical:

PPI rate (discharge, 30 days) MACCE** (discharge, 30 days): All-cause death, MI, stroke, reoperation Major vascular complications

Hemodynamic/Echocardiographic:

Valve orifice area, mean gradient, peak velocity Degree of stenosis/regurgitation LVEF (immediate, discharge, 30 days)

Functional: NYHA Class improvement (discharge, 30 days)

*VARC-3: Valve Academic Research Consortium-3 criteria for technical success.

**MACCE: Major Adverse Cardiac and Cerebrovascular Events.

6. Statistical Analysis \& Sample Size Hypothesis: Superiority of VitaFlow Liberty® Flex

Assumptions:

Historical composite endpoint rate (non-steerable systems): 38% Expected composite rate (steerable system): 21% Superiority margin (Δ1): 0% Power: 80% \| One-sided α: 2.5% \| Dropout: 5% Sample Size: 232 subjects (116 per arm)

Analysis:

Primary endpoint: Chi-square/Fisher's exact test Secondary endpoints: Mixed-effects models accounting for site variability Subgroup analyses: Valve size, center volume, baseline aortic-LV angle

7. Study Procedures

Screening (≤30 days pre-op): Echocardiography, CTA, NYHA assessment, informed consent.

Procedure: TAVR under standard anesthesia. Randomization pre-insertion. Discharge (≤7 days): Echo, ECG, NYHA, MACCE/vascular complication assessment. 30-Day Visit: Clinical exam, echo, ECG, lab tests, NYHA, MACCE. 12-Month Follow-up: Telephone assessment for mortality/MACCE.

8. Ethical \& Regulatory Considerations

Approved by institutional review boards (IRBs) at all sites. Conducted per ICH-GCP, Declaration of Helsinki, and Chinese regulatory requirements.

Independent DMC reviews safety data quarterly.

9. Significance and Innovation

This trial addresses a critical unmet need in TAVR: improving outcomes in patients with challenging aortic anatomies. If superiority is demonstrated, the steerable delivery system may become the preferred option for:

Reducing PPI rates (linked to anatomical precision) Mitigating PVL (via optimal deployment) Avoiding ViV (through recapture/repositioning) Enhancing first-attempt success in tortuous anatomies

Conclusion:

This rigorously designed RCT will provide Level A evidence on the clinical utility of steerable TAVR technology in high-risk anatomies, potentially establishing a new standard for managing complex AS patients.

03

Conditions studied

  • Aortic Valve Stenosis

Keywords

  • TAVR
  • Steerable Delivery System
  • Aortic Stenosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of severe aortic stenosis, defined as: echocardiographically confirmed peak aortic valve velocity ≥4.0 m/s, or mean aortic valve gradient ≥40 mmHg, or aortic valve area (AVA) ≤1.0 cm2 (or AVA index ≤0.6 cm2/m2);
  2. Preoperative cardiac and great vessel CT angiography (CTA) with 3D reconstruction demonstrating an aortic-left ventricular angle >60°, indicating potential challenges for arch crossing and valve crossing;
  3. (NYHA) functional class ≥II;
  4. Voluntary participation in the study with signed .

Exclusion criteria

Exclusion Criteria:

  1. Known allergy or intolerance to components of the or control devices (e.g., nitinol) or contrast agents;
  2. or known allergy to anticoagulant or antiplatelet therapy, rendering the patient unable to tolerate such treatment;
  3. Known active infective endocarditis or other active infections;
  4. Known severe vascular disease that would preclude safe prosthetic valve implantation;
  5. Ascending aorta width ≥55mm;
  6. Pre-procedural imaging shows aortic root anatomy unsuitable for transcatheter aortic valve implantation (including aortic root calcification that may affect proper valve expansion);
  7. Pre-procedural echocardiography shows intracardiac mass, left ventricular or left atrial thrombus, or vegetation;
  8. Acute myocardial infarction within 30 days prior to procedure (defined as Q-wave MI or non-Q-wave MI);
  9. Concomitant severe mitral or tricuspid regurgitation;
  10. Concomitant cardiogenic shock or hemodynamic instability requiring inotropic support, mechanical ventilation, or mechanical cardiac assistance;
  11. Concomitant severe left ventricular dysfunction (defined as LVEF\<20%);
  12. Concomitant hematologic abnormalities defined as leukopenia (WBC count \<3×109/L), thrombocytopenia ( count \<30×109/L), history of bleeding diathesis or coagulopathy, or hypercoagulable state;
  13. Female subjects known to be pregnant or breastfeeding;
  14. Subjects currently participating in or planning to participate in other drug or device clinical studies within 12 months postoperatively; Any other condition that the investigator or heart team deems may hinder the subject's safe participation in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
232 participants (estimated)

Study arms

  • Experimental
    Investigational Device

    Transcatheter Aortic Valve Retrievable and Controllable Flex Delivery System (VitaFlow Liberty® Flex)

    Device: Transcatheter Aortic Valve Replacement

  • Active comparator
    Control Device

    Transcatheter Aortic Valve and Delivery System (Self-Expanding Valve, Non-Controllable Flex Delivery System)

    Device: Transcatheter Aortic Valve Replacement

Interventions

  • DeviceTranscatheter Aortic Valve Replacement

    Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR) has gradually emerged as a new treatment option for patients with severe aortic stenosis who are ineligible for open-heart valve replacement or at high surgical risk.

06

What researchers measure

Primary outcomes

  1. the number of occurrences/total number of occurrences

    Incidence of composite endpoint events before discharge (permanent pacemaker implantation, valve-in-valve, or moderate-to-severe paravalvular leak) calculated as number of occurrences/total number of occurrences

    Time frame: Perioperative/Periprocedural"

Secondary outcomes

  1. Incidence of valve-in-valve

    Incidence of valve-in-valve calculated as: Occurred/Total

    Time frame: Perioperative/Periprocedural

  2. Incidence of Moderate-to-severe paravalvular leak

    Incidence of Moderate-to-severe paravalvular leak calculated as: Occurred/Total

    Time frame: Perioperative/Periprocedural

  3. Incidence of Other technical assistance crossing rate

    Incidence of Other technical assistance crossing rate (immediately post-procedure) calculated as: Occurred/Total

    Time frame: Perioperative/Periprocedural

  4. Incidence of valve retrievals

    Incidence of valve retrievals calculated as: Occurred/Total

    Time frame: Perioperative/Periprocedural

  5. Valve implantation depth calculated as Intraoperative images

    Valve implantation depth calculated as Intraoperative images

    Time frame: Perioperative/Periprocedural

  6. Incidence of Permanent Pacemaker Implantation

    Incidence of Permanent Pacemaker Implantation calculated as: Occurred/Total

    Time frame: Perioperative/Periprocedural, 30 days,

  7. Arch Crossing and Valve Crossing Performance calculated as assessment scale

    Arch Crossing and Valve Crossing Performance calculated as assessment scale

    Time frame: Perioperative/Periprocedural

  8. Number of participants with Valve Performance Evaluation

    Valve Performance Evaluation, Including: Valve Orifice Area, Mean Transvalvular Pressure Gradient, Peak Transvalvular Velocity, Degree of Valve Stenosis, Degree of Valve Regurgitation, Degree of Paravalvular Leak, Left Ventricular Ejection Fraction (LVEF) calculated as cardiac uhrasonography

    Time frame: Perioperative/Periprocedural, 30 days,

  9. NYHA Functional Class Assessment NYHA classification

    NYHA Functional Class Assessment NYHA classification: Divided into four levels, Grade I: No discomfort in daily activities, and no restriction in physical activities. Grade II: Mild activity restriction, no symptoms at rest, but daily activities (such as climbing stairs) can cause fatigue and palpitation. Grade III: obvious activity limitation, no symptoms at rest, but slight activity (such as walking) will cause symptoms. Grade Ⅳ: There are symptoms at rest, and any activity aggravates discomfort.

    Time frame: Perioperative/Periprocedural, 30 days

  10. Incidence of Major Adverse Cardiac and Cerebrovascular Events (MACCE)

    Incidence of Major Adverse Cardiac and Cerebrovascular Events (MACCE),MACCE Includes: All-Cause Mortality, Myocardial Infarction, All Stroke, Reoperation Due to Valve Dysfunction calculated as: Occurred/Total

    Time frame: Perioperative/Periprocedural, 30 days,

  11. Incidence of Major Vascular Complications

    Incidence of Major Vascular Complications calculated as: Occurred/Total

    Time frame: Perioperative/Periprocedural, 30 days

  12. Procedural Success Rate (VARC-3 Definition)

    Procedural Success Rate (VARC-3 Definition) calculated as: Occurred/Total

    Time frame: Perioperative/Periprocedural

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002 Dec 10;106(24):3006-8. doi: 10.1161/01.cir.0000047200.36165.b8. PubMed 12473543 ↗
  • Grube E, Laborde JC, Gerckens U, Felderhoff T, Sauren B, Buellesfeld L, Mueller R, Menichelli M, Schmidt T, Zickmann B, Iversen S, Stone GW. Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation. 2006 Oct 10;114(15):1616-24. doi: 10.1161/CIRCULATIONAHA.106.639450. Epub 2006 Oct 2. PubMed 17015786 ↗
  • Supino PG, Borer JS, Preibisz J, Bornstein A. The epidemiology of valvular heart disease: a growing public health problem. Heart Fail Clin. 2006 Oct;2(4):379-93. doi: 10.1016/j.hfc.2006.09.010. No abstract available. PubMed 17448426 ↗
  • Carabello BA, Paulus WJ. Aortic stenosis. Lancet. 2009 Mar 14;373(9667):956-66. doi: 10.1016/S0140-6736(09)60211-7. Epub 2009 Feb 21. PubMed 19232707 ↗
  • Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010 Oct 21;363(17):1597-607. doi: 10.1056/NEJMoa1008232. Epub 2010 Sep 22. PubMed 20961243 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Aug 2026, 13 months after the start.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 13 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 28, 2025
StartActual
Jul 30, 2025
Primary completionEst.
Aug 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07145463
Collaborators
First Hospital of China Medical University, The Affiliated Hospital of Qingdao University, First Affiliated Hospital of Fujian Medical University, Renmin Hospital of Wuhan University, The First Affiliated Hospital of Nanchang University, The Second Affiliated Hospital of Dalian Medical University, Guangdong Provincial People's Hospital, General Hospital of Ningxia Medical University, Sichuan Provincial People's Hospital, Second Affiliated Hospital of Nanchang University, Tang-Du Hospital
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Jul 30, 2025
Primary completion
Aug 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 28, 2025

Study contacts

Wenzhi Pan, MD
Contact
peden@sina.com
+86 13774475922
Wenzhi Pan, MD
study chair · Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion